The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://isaiahqmpi914155.topbloghub.com/45554143/glp-3-retatrutide-a-comparative-analysis